Triazoloquinazolines as human A3 adenosine receptor antagonists: A QSAR study

International Journal of Molecular Sciences

Volumn 7, Issue 11, 2006, Pages 485-496

  Kim, Dooil ^a,b   Hong, Suk In ^b   Lee, Dae Sil ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Korea University   (South Korea)

Author keywords

Human A 3 receptor; QSAR; Triazoloquinazoline adenosine antagonist

Indexed keywords

ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; TRIAZOLOQUINAZOLINE DERIVATIVE;

ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG STRUCTURE; HYDROPHOBICITY; PARAMETER; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 33947322016     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/i7110485     Document Type: Article

References (24)

1. Iismaa, T. P.; Biden, T. J.; Shine, J.; G Protein-Coupled Receptors Springer-Verlag: Heidelberg, 1995.
2. Olah, M. E.; Stiles, G. L. Adenosine Receptor Subtypes: Characterization and Therapeutic Regulation, Annu. Rev. Pharmacol. Toxicol. 1995, 35, 581-606.
3. Downey, J. M.; Cohen, M. V.; Ytrehus, K.; Liu, Y. Cellular mechanisms in ischemic preconditioning: The role of adenosine and protein kinase C. Ann. NY Acad. Sci. 1994, 723, 82-98.
4. De Zwart, M.; Kourounakis, A.; Kooijman, H.; Spek, A. L.; Link, R. 5′-N-substituted carboxamidoadenosines as agonists for adenosine receptors. J. Med. Chem. 1999, 42, 1384-1392.
5. Hannon, J. P.; Pfannkuche, H. J.; Fozard, J. R. A role for mast cells in adenosine A3 receptormediated hypotension in the rat. Br. J. Pharmacol. 1995, 115, 945-952.
6. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 1993, 268, 16887-16890.
7. 3-adenosine receptors: Design of selective ligands and therapeutic prospects. Drugs of the Future 1995, 20, 689-699.
8. Ji, X. D.; Melman, N.; Jacobson, K. A. Interactions of flavonoids and other phytochemicals with adenosine receptors. J. Med. Chem. 1996, 39, 781-788.
9. Moro, S.; van Rhee, A. M.; Sanders, L. H.; Jacobson, K. A. Flavonoid derivatives as adenosine receptor antagonists: A comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. J. Med. Chem. 1998, 41, 46-52.
10. Li, A. H.; Moro, S.; Forsyth, N.; Melman, N.; Ji, X. D.; Jacobson, K. A. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4- dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J. Med. Chem. 1999, 42, 706-721.
11. Van Rhee, M.; Jiang, J. L.; Melman, N.; Olah, M. E.; Stiles, G. L.; Jacobson, K. A. Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: Selectivity for A3 receptors. J. Med. Chem. 1996, 39, 2980-2989.
12. Jiang, J. L.; van Rhee, A. M.; Melman, N.; Ji, X. D.; Jacobson, K. A. 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 1996, 39, 4667-4675.
13. Kim, Y. C.; Ji, X. D.; Jacobson, K. A. Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J. Med. Chem. 1996, 39, 4142-4148.
14. Kim, Y. C.; de Zwart, M.; Chang, L.; Moro, S.; Kunzel, J. K.; Von, F. D.; Melman, N.; Ijzerman, A. P.; Jacobson, K. A. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A(2B) and A3 receptor subtypes. J. Med. Chem. 1998, 41, 2835-2845.
15. Jacobson, K. A.; Park, K. S.; Jiang, J. L.; Kim, Y. C.; Olah, M. E.; Stiles, G. L.; Ji, X. D. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 1997, 36, 1157-1165.
16. 3 adenosine antagonists: Structural homology and receptor docking. J. Chem. Inf. Comput. Sci. 1998, 38, 1239-1248.
17. Hansch, C.; Fujita, T. p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure. J. Am. Chem. Soc. 1964, 86, 1616-1630.
18. Halgren, T. A. Representation of van der Waals (vdW) interactions in molecular mechanics force fields: Potential form, combination rules, and vdW parameters. J. Am. Chem. Soc. 1992, 114, 7827-7843.
19. Halgren, T. A.; Nachbar, R. B. Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J. Comp. Chem. 1996, 19, 587-615.
20. Rappé, A. K.; Goddard, W. A. Charge equilibration for molecular dynamics simulations. J. Phys. Chem. 1991, 95, 3358-3363.
21. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches, VCH: WeinHeim, 1993; Methods and principles in medicinal chemistry, Vol. 1.
22. Verloop, A.; Hoogenstraaten, W.; Tipker, J. Drug Design, Ariens, E. J., ed., Academic Press: New York, 1976; Vol. VII.
23. Verloop, A. The STERIMOL Approach to Drug Design, Marcel Dekker, New York, 1987.
24. Stanton, T.; Jurs, P. C. Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies. Anal. Chem. 1990, 62, 2323-2329.